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Successful deliveries from patients supported by axial flow left ventricular devices
have been previously reported. We present the first case of a successful
pregnancy and birth in a patient with a centrifugal-flow left ventricular assist
device. A 24-year-old female with methamphetamine-induced cardiomyopathy and
end-stage congestive heart failure supported by a HeartWare™ ventricular assist
device (Medtronic) presented two years after device implantation with an
unplanned pregnancy at 11-weeks of gestation. Following a multidisciplinary
evaluation by experts in advanced heart failure, maternal fetal medicine,
cardiothoracic surgery, anesthesia, ethics, psychiatry, and palliative care, an
advanced plan of care was established. An elective induction of labor was
scheduled for the 34th week of gestation. Given poor labor progression despite
maximal induction efforts, the patient was transferred to a cardiothoracic operating
room where she delivered a healthy baby boy via Cesarean section under close
hemodynamic monitoring by advanced heart failure and cardiothoracic surgery
teams.
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Background
Left ventricular assist devices (LVADs) are rapidly expanding as an established
therapeutic modality in patients with advanced heart failure (AHF) as a destination
therapy. In women with end stage heart failure who are supported by LVADs,
conception is considered “high risk” for both the mother and the fetus and is
contraindicated.1 We report the case of an unplanned pregnancy and successful
delivery in an LVAD-supported patient.

Case Report
A 24-year-old female with a history of stage D, biventricular heart failure secondary
to non-ischemic cardiomyopathy (likely from methamphetamine use) was
supported by a centrifugal-flow LVAD (HeartWare™ ventricular assist device
[HVAD], Medtronic). Her LVAD postoperative recovery required a short course of
intravenous milrinone for right ventricular (RV) failure; milrinone was discontinued
prior to discharge. Early after LVAD implantation, right heart catherization showed
a right atrial pressure (RAP) of 6 mmHg and a pulmonary artery (PA) pressure of
4/17 mmHg at an LVAD speed of 2560 rpm. Despite multidisciplinary efforts,
including close follow up with psychiatry to improve compliance, the patient
struggled with polysubstance abuse and medication non-compliance, including
contraception. Her past medical history was also significant for iron deficiency
anemia, deep venous thrombosis, pelvic inflammatory disease, anxiety,
depression, post-traumatic stress disorder, and active tobacco use.
Two years post-LVAD implantation, the patient presented to the emergency
department complaining of non-exertional chest pain and lethargy.. Her physical
examination, device evaluation, electrocardiogram, and cardiac biomarkers were
unremarkable, but her urine drug screen was positive for amphetamines,
benzodiazepines, phencyclidine, and tetrahydrocannabinol. Her international
normalized ratio was 1. She had a positive urine pregnancy test, and an obstetric
ultrasound confirmed a single intrauterine fetus with an estimated gestational age
of 11-weeks. She reported intentional non-compliance with the recommendation
for effective contraception.
A multidisciplinary evaluation was performed by experts in AHF, maternal fetal
medicine (MFM), cardiothoracic surgery (CTS), anesthesia, ethics, psychiatry, and
palliative care. Inherent and potentially unknown maternal and fetal risks during all
stages of pregnancy while on LVAD support as well as risks of intrauterine
exposure to potentially teratogenic medications were explained to the patient.
Understanding the risks to herself and her baby, the patient elected to continue
with the pregnancy.
Enoxaparin was selected as outpatient anticoagulation strategy with close Factor
Xa monitoring. In consultation with MFM, CTS, AHF, and anesthesia services, the
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patient was scheduled for close outpatient follow up and an elective induction of
labor at 34-weeks of gestation. A plan was devised for labor to happen in the CTS
intensive care unit (ICU) with invasive hemodynamic monitoring and with all teams
physically available during delivery. A contingency plan was also implemented for
potential medical admissions prior to delivery. If admission was needed, the
patient was to be taken directly to the cardiac ICU with close MFM and CTS
consultation and follow up. Weekly followup appointments were schedued with the
high-risk obstetric and AHF service.
The patient was closely monitored throughout her pregnancy and tolerated the
hemodynamic changes of pregnancy well. She remained on chronic low-dose
benzodiazepines for management of uncontrollable anxiety. She was also started
on buprenorphine/naloxone to prevent heroin and opioid abuse relapse. She
underwent frequent urine drug testing, and all screens remained negative. Monthly
transthoracic echocardiograms revealed stable RV and left ventricular (LV) systolic
function along with minimal progressive increase in LV internal diameter end
diastole (Table 1). To optimize the patient’s mean arterial pressure (MAP),
nifedipine was added after her third outpatient visit. Based on clinical and
echocardiographic findings, the VAD speed was increased by 40 and 20 RPM at
the 30th and 31st week of gestation, respectively (final speed of 2780 RPM). Her
RV size and function remained stable despite the increased LVAD speed, volume
expansion, and increased cardiac output related to pregnancy.
She was admitted to the hospital during her 34th week of gestation. Arterial line
and pulmonary artery catheters were placed for invasive hemodynamic monitoring.
With the LVAD speed at 2780 rpm, the RHC findings were: RAP = 9 mmHg, PA
pressure = 35/19 mmHg, MAP = 84 mmHg. Nifedipine was stopped, and as
needed intravenous hydralazine was started with the goal MAP of less than
85mmHg. Enoxaparin was held, and a heparin drip started in preparation for labor.
Induction of labor was started the next morning in the CTS-ICU with oxytocin
infusion and artificial rupture of the membranes. Given failed labor progression
despite maximal induction efforts, the patient was transferred to the CTS operating
room where she underwent a Cesarean section (CS) with epidural anesthesia.
She delivered a 2296 g male with one and five minute APGAR scores of 8 and 9,
respectively. A levonorgestrel-releasing intrauterine device was placed inside the
uterine cavity before closure of the walls. Beside self-limited, minimal increases in
the pulmonary artery pressure, the patient remained hemodynamically stable
throughout the procedure.
Her postoperative course was complicated by anemia requiring transfusion.
Multifocal pneumonia and bacteremia were successfully treated with broadspectrum antibiotics in consultation with the infectious disease service. Both
mother and the baby remained stable and asymptomatic on their outpatient
followups.
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Discussion and Literature Review
This is the first reported case of a successful pregnancy and delivery in a patient
with a centrifugal-flow HVAD. The first two cases of pregnancy on LVAD support
were reported by LaRue, et al.1 and Sims, et al.2 in 2011, and the third case was
reported in 2017 by Makdisi et al.3 Table 2 provides details about characteristics of
prior reported cases. All three prior cases involved patients with HeartMate II
devices (Abbott) that were implanted 6 to 11-months prior to the diagnosis of
pregnancy. The gestational age at presentation ranged from 6 to 34-weeks. The
first two cases delivered by CS;1,2 however, Sims et al reported a normal vaginal
delivery.3 All cases involved switching from warfarin to heparin and/or low
molecular heparin. To meet the increased cardiac output associated with
pregnancy, the LVAD speed was increased in a stepwise fashion in all three cases
with echocardiographic and clinical response monitoring. Postpartum anemia was
reported in all three cases.
Our patient’s clinical course differed in some aspects with the prior reported cases.
Our patient had an HVAD—a centrifugal pump with lower rotational speeds (20003000 RPM) as compared to HeartMate II, an axial-flow device which has higher
rotational speeds (9000-10,000 RPM). Unlike our patient, in the two prior cases,
newborns had complications mostly related to prematurity. Despite remaining on
benzodiazepines and the buprenorphine/naloxone combination during pregnancy,
our patient’s newborn had normal APGAR scores and an uncomplicated newborn
transition.
Our patient also had history of biventricular failure requiring a short course of
milrinone after her initial HVAD implantation. Despite the increased LVAD speeds
during gestation and the expected increase in maternal plasma volume of up to
40–50% near term, her RV did not require any inotropic support.
Even though our case and the three prior reported cases had favorable outcomes,
risks and potential complications of pregnancy and labor while on LVAD remain
largely unknown and potentially catastrophic. A multidisciplinary approach
involving the AHF team, CTS, anesthesiology, MFM, psychiatry, psychology,
ethics, and palliative care as well as social workers and case managers is key in
optimal management. Patients will require close outpatient monitoring and
advanced planning for a multidisciplinary inpatient care prior to scheduled delivery.
With increasing use of LVAD in treatment of non-ischemic cardiomyopathy,
addtional cases of unplanned pregnancy are inevitable. The uteroplacental unit is
characterized by a high-flow, low-resistance circulation, but there is limited data on
normal placental growth with LVAD. These reported cases of successful
pregnancy on LVAD with appropriately grown fetuses provide anecdotal evidence
to the theory that continuous flow from LVADs can potentially support the
uteroplacental circulation in an otherwise normal pregnancy. Comparative studies
are necessary regarding anticoagulation strategies and to identify optimal targets
for Factor Xa levels in different devices. Future multicenter studies should redefine
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strategies regarding optimal timing and standardization of LVAD speed increments
at various stages of pregnancy.
Pregnancy after LVAD presents signficant risk for both mother and fetus and is
generally contraindicated. However, many young women of childbearing age with
an LVAD may desire children. Some of these patients will receive cardiac
transplantation. While there have been many successful pregnancies in postcardiac transplant patients reported in the literature, long-term outcome data is
limited. Moreover, many patients might not be eligible for cardiac transplantation
due to different reasons (e.g. high antibody titers); therefore, many young women
of childbearing age could be deprived of a life-fulfilling experience after LVAD
implantation as a destination therapy. Theoretically, certain fetal risks during
pregnancy with LVAD are likely to be less due to minimal exposure to teratogenic
medications that are used in patients with cardiac transplantation. We need to
build a consensus, integrate research and identify centers that are willing to
support and invest in research on pregnancy with LVAD support via a
multidisciplinary approach. It remains to be seen whether maternal and fetal risks
can be minimized so that certain childbearing women can have successful delivery
while being supported with LVAD.
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